Immunotherapies for hepatocellular carcinoma
JM Llovet, F Castet, M Heikenwalder… - Nature reviews Clinical …, 2022 - nature.com
Liver cancer, more specifically hepatocellular carcinoma (HCC), is the second leading
cause of cancer-related death and its incidence is increasing globally. Around 50% of …
cause of cancer-related death and its incidence is increasing globally. Around 50% of …
DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy
R Huang, PK Zhou - Signal transduction and targeted therapy, 2021 - nature.com
Genomic instability is the hallmark of various cancers with the increasing accumulation of
DNA damage. The application of radiotherapy and chemotherapy in cancer treatment is …
DNA damage. The application of radiotherapy and chemotherapy in cancer treatment is …
[HTML][HTML] NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Hepatocellular carcinoma (HCC) can have viral or non-viral causes,,,–. Non-alcoholic
steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved …
steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved …
[PDF][PDF] Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child‐Pugh A and B cirrhosis: a …
Abstract Background and Aims Atezolizumab plus bevacizumab (AtezoBev) is the standard
of care for first‐line treatment of unresectable HCC. No evidence exists as to its use in …
of care for first‐line treatment of unresectable HCC. No evidence exists as to its use in …
[HTML][HTML] Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective …
B Marinelli, E Kim, A D'Alessio, M Cedillo… - … for immunotherapy of …, 2022 - ncbi.nlm.nih.gov
Background Immune checkpoint inhibitors (ICIs) have revolutionized treatment of advanced
hepatocellular carcinoma. Integrated use of transarterial chemoembolization (TACE), a …
hepatocellular carcinoma. Integrated use of transarterial chemoembolization (TACE), a …
Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice
Systemic therapy for advanced hepatocellular carcinoma has expanded at an
unprecedented pace over the past 5 years. After tyrosine kinase inhibitors dominated the …
unprecedented pace over the past 5 years. After tyrosine kinase inhibitors dominated the …
Immune checkpoint inhibitors for child-pugh class B advanced hepatocellular carcinoma: a systematic review and meta-analysis
Importance Immune checkpoint inhibitors (ICIs) are increasingly used in patients with
advanced hepatocellular carcinoma (HCC). However, data on ICI therapy in patients with …
advanced hepatocellular carcinoma (HCC). However, data on ICI therapy in patients with …
[HTML][HTML] Efficacy and safety of frontline systemic therapy for advanced HCC: a network meta-analysis of landmark phase III trials
Background & Aims Direct comparisons across first-line regimens for advanced
hepatocellular carcinoma are not available. We performed a network metanalysis of phase …
hepatocellular carcinoma are not available. We performed a network metanalysis of phase …
[HTML][HTML] Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: evidence from an FDA pooled analysis of landmark clinical …
Purpose The development of treatment-related adverse events (trAE) correlates favorably
with clinical outcomes in multiple studies of patients receiving immune checkpoint inhibitors …
with clinical outcomes in multiple studies of patients receiving immune checkpoint inhibitors …
[HTML][HTML] Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
TF Greten, GK Abou-Alfa, AL Cheng… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Patients with advanced hepatocellular carcinoma (HCC) have historically had few options
and faced extremely poor prognoses if their disease progressed after standard-of-care …
and faced extremely poor prognoses if their disease progressed after standard-of-care …